Aspen Aerogels, Inc. (NYSE:ASPN) Receives Average Rating of “Hold” from Analysts

Aspen Aerogels, Inc. (NYSE:ASPN) has earned a consensus rating of “Hold” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $5.9375.

A number of brokerages have recently commented on ASPN. Barclays lifted their target price on shares of Aspen Aerogels from $4.00 to $5.00 and gave the company an “underweight” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded shares of Aspen Aerogels from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. B. Riley Financial restated a “buy” rating on shares of Aspen Aerogels in a research note on Friday, August 7th. Roth Capital reaffirmed a “buy” rating and issued a $7.75 target price on shares of Aspen Aerogels in a report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aspen Aerogels in a research note on Wednesday, June 24th.

Aspen Aerogels Trading Up 3.0%

NYSE:ASPN opened at $4.90 on Friday. The stock’s 50 day moving average price is $5.20 and its 200 day moving average price is $4.74. The company has a market capitalization of $406.90 million, a PE ratio of -3.20 and a beta of 2.97. The company has a quick ratio of 2.24, a current ratio of 2.52 and a debt-to-equity ratio of 0.36. Aspen Aerogels has a 52-week low of $2.30 and a 52-week high of $9.35.

Aspen Aerogels (NYSE:ASPN) last issued its quarterly earnings data on Thursday, August 6th. The construction company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The company had revenue of $49.85 million during the quarter, compared to analysts’ expectations of $42.42 million. Aspen Aerogels had a negative return on equity of 31.12% and a negative net margin of 62.45%.Aspen Aerogels has set its Q3 2026 guidance at -0.110–0.070 EPS. On average, research analysts anticipate that Aspen Aerogels will post -0.69 EPS for the current year.

Institutional Trading of Aspen Aerogels

A number of hedge funds have recently added to or reduced their stakes in ASPN. Royal Bank of Canada grew its stake in shares of Aspen Aerogels by 95.8% in the 1st quarter. Royal Bank of Canada now owns 8,523 shares of the construction company’s stock valued at $29,000 after purchasing an additional 4,169 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Aspen Aerogels during the fourth quarter worth $30,000. Clarus Group Inc. acquired a new stake in shares of Aspen Aerogels during the first quarter worth $36,000. California State Teachers Retirement System grew its position in Aspen Aerogels by 64.2% in the 2nd quarter. California State Teachers Retirement System now owns 5,890 shares of the construction company’s stock valued at $37,000 after buying an additional 2,302 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Aspen Aerogels in the 4th quarter valued at $40,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Aspen Aerogels

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.